Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Minimal residual disease (MRD) assessment is incorporated in an increasing number of
multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Background Standard-of-care treatment for patients with newly diagnosed multiple myeloma
includes combination therapies for patients who are not eligible for autologous stem-cell …

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide,
bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on …

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces
apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has …